{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:03Z","timestamp":1790775123732,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology. Benefits include anti-inflammatory effects, protection against thrombosis, and improved control of hyperglycemia and hyperlipidemia. In general, both the therapeutic advantages and the toxic effects of the drugs correlate with the dose and the duration of therapy. Here we summarize the current literature regarding the administration and the safety profile of HCQ in management of rheumatologic disease and focus on the most recent revised American Academy of Ophthalmology (AAO) guidelines for prevention and detection of hydroxychloroquine retinopathy to help guide therapeutic decision-making for patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The risk of antimalarial-induced retinal toxicity is better predicted by calculating the daily dosage based on 5\u200amg\/kg total body weight rather than 6.5\u200amg\/kg lean body weight and reducing dosage in patients with risk factors such as renal failure. The risk of retinal toxicity after 5 years is substantially increased even when these guidelines are followed; hence dose reduction is appropriate with long-term use. Newer techniques provide improved detection of early signs of retinal damage. These advances are reflected in the revised AAO guidelines 2016, which are in part based on the retrospective study by Melles and Marmor of HCQ toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The most important changes in practice guidelines include dose calculation based on total body weight, dose reduction after long-term use, and intensified screening with techniques including optical coherence tomography (OCT) after 5 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000500","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T16:13:24Z","timestamp":1520439204000},"page":"249-255","source":"Crossref","is-referenced-by-count":43,"title":["Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update"],"prefix":"10.1097","volume":"30","author":[{"given":"Nada","family":"Abdulaziz","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali R.","family":"Shah","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"McCune","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/0961203393002001011","article-title":"Introduction to symposium on antimalarial therapy and lupus","volume":"2","author":"Rynes","year":"1993","journal-title":"Lupus"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0022-3565(25)26585-5","article-title":"Effects of hydroxychloroquine on the growth of mammalian cells in vitro","volume":"141","author":"Gabourel","year":"1963","journal-title":"J Pharmacol Exp Ther"},{"issue":"(suppl 1)","key":"R4-20230828","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1177\/0961203396005001021","article-title":"The history of antimalarials","volume":"5","author":"Wallace","year":"1996","journal-title":"Lupus"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).; American Academy of Ophthalmology","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","article-title":"New concepts in antimalarial use and mode of action in dermatology","volume":"20","author":"Kalia","year":"2007","journal-title":"Dermatol Ther"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00280-016-3197-1","article-title":"Research progress of hydroxychloroquine and autophagy inhibitors on cancer","volume":"79","author":"Shi","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2015.07.012","article-title":"Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy","volume":"160","author":"Leung","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","article-title":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis","volume":"46","author":"Munster","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3899\/jrheum.150379","article-title":"Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence","volume":"42","author":"Durcan","year":"2015","journal-title":"J Rheumatol"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","article-title":"Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus","volume":"54","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)","volume":"72","author":"Costedoat-Chalumeau","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R13-20230828","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfx318","article-title":"Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?","author":"Cunha","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2015.09.064","article-title":"The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study","volume":"74","author":"Chasset","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J","article-title":"Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension","volume":"42","author":"Furst","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/archderm.1959.01560230043008","article-title":"Visual disturbances with antimalarial drugs, with particular reference to chloroquine keratopathy","volume":"80","author":"Hobbs","year":"1959","journal-title":"Arch Dermatol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00007611-199203000-00010","article-title":"Ocular safety of hydroxychloroquine sulfate (Plaquenil)","volume":"85","author":"Bernstein","year":"1992","journal-title":"South Med J"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/eye.2016.298","article-title":"Hydroxychloroquine retinopathy","volume":"31","author":"Yusuf","year":"2017","journal-title":"Eye (Lond)"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ajo.2006.12.042","article-title":"Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography","volume":"143","author":"Lyons","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/acr.20133","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res(Hoboken)"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0950-3579(05)80004-4","article-title":"Antimalarials in rheumatic diseases","volume":"4","author":"Tett","year":"1990","journal-title":"Baillieres Clin Rheumatol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/art.39194","article-title":"Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus","volume":"67","author":"Jallouli","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"(suppl 1)","key":"R26-20230828","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000267861","article-title":"Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine","volume":"27","author":"Toimela","year":"1995","journal-title":"Ophthalmic Res"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(05)78925-X","article-title":"Hydroxychloroquine and retinal safety","volume":"351","author":"Block","year":"1998","journal-title":"Lancet"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10633-008-9130-0","article-title":"Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: review of mfERG ring ratios in Plaquenil toxicity","volume":"118","author":"Lyons","year":"2009","journal-title":"Doc Ophthalmol"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaophthalmol.2014.1099","article-title":"Effect of disease stage on progression of hydroxychloroquine retinopathy","volume":"132","author":"Marmor","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ophtha.2014.07.018","article-title":"Pericentral retinopathy and racial differences in hydroxychloroquine toxicity","volume":"122","author":"Melles","year":"2015","journal-title":"Ophthalmology"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archopht.122.7.973","article-title":"Multifocal electroretinographicevalution of long term hydroxychloroquine users","volume":"122","author":"Maturi","year":"2004","journal-title":"Arch Ophtalmol"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/archophthalmol.2011.371","article-title":"Comparison of screening procedures in hydroxychloroquine toxicity","volume":"130","author":"Marmor","year":"2012","journal-title":"Arch Ophtalmol"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/rheumatology\/kev357","article-title":"Hydroxychloroquine-related retinal toxicity","volume":"55","author":"Ding","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archopht.125.6.775","article-title":"High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy","volume":"125","author":"Rodriguez-Padilla","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1167\/iovs.05-1290","article-title":"Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine\/hydroxychloroquine","volume":"47","author":"Kellner","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2147\/OPTH.S66527","article-title":"Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy","volume":"8","author":"Browning","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2133.1999.02600.x","article-title":"Ocular toxicity and hydroxychloroquine: guidelines for screening","volume":"140","author":"Jones","year":"1999","journal-title":"Br J Dermatol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/BOR.0000000000000173","article-title":"Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?","volume":"27","author":"McCune","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/archophthalmol.2010.321","article-title":"Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy","volume":"129","author":"Michaelides","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R40-20230828","first-page":"290","article-title":"Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients","volume":"23","author":"Ruiz","year":"1991","journal-title":"Ann Ophthalmol"},{"key":"R41-20230828","first-page":"237","article-title":"Long-term course of antimalarial maculopathy after cessation of treatment","volume":"27","author":"Easterbrook","year":"1992","journal-title":"Can J Ophthalmol"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9394(79)90743-8","article-title":"Long-term course of chloroquine retinopathy after cessation of medication","volume":"88","author":"Brinkley","year":"1979","journal-title":"Am J Ophthalmol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002281-201805000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:04:54Z","timestamp":1785855894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201805000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000500","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}